Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NNC0385-0434
- Development stage
- Phase 2
- Lead developer
- Novo Nordisk
- Modality
- Peptides, Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
NNC0385-0434 is an orally administered peptide drug that mimics the EGF-A domain of the human LDL receptor. It acts as a competitive inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9), binding to free PCSK9 and preventing its interaction with the LDL receptor. This mechanism increases LDL receptor availability on hepatocytes and enhances clearance of low-density lipoprotein (LDL) cholesterol from plasma. Developed by Novo Nordisk, it was investigated for hypercholesterolemia and type 2 diabetes mellitus in high-risk cardiovascular patients but was discontinued after phase II trials due to portfolio considerations[1][3][4].
- Other names
- NNC 03850434NNC03850434NNC-03850434NNC 0385 0434NNC0385 0434NNC-0385 0434
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on NNC0385-0434.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NNC0385-0434.